Lexicon Historical Income Statement
| LXRX Stock | USD 0.78 0.00 0.000004% |
Historical analysis of Lexicon Pharmaceuticals income statement accounts such as Gross Profit of 956.7 K can show how well Lexicon Pharmaceuticals performed in making a profits. Evaluating Lexicon Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Lexicon Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Lexicon Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lexicon Pharmaceuticals is a good buy for the upcoming year.
Lexicon |
About Lexicon Income Statement Analysis
Lexicon Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Lexicon Pharmaceuticals shareholders. The income statement also shows Lexicon investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Lexicon Pharmaceuticals Income Statement Chart
Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Total Revenue
Total revenue comprises all receipts Lexicon Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Lexicon Pharmaceuticals. It is also known as Lexicon Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Most accounts from Lexicon Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Lexicon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.At this time, Lexicon Pharmaceuticals' Interest Expense is fairly stable compared to the past year. Research Development is likely to rise to about 97.4 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 473.7 K in 2025.
| 2024 | 2025 (projected) | Extraordinary Items | 3.6M | 3.2M | Reconciled Depreciation | 459K | 436.1K |
Lexicon Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Lexicon Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lexicon Pharmaceuticals income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 2.9M | 292K | 427K | 554K | 498.6K | 473.7K | |
| Interest Expense | 14.5M | 802K | 2.8M | 13.1M | 15.1M | 15.8M | |
| Total Revenue | 24.0M | 298K | 139K | 1.2M | 1.1M | 1.0M | |
| Gross Profit | 22.1M | (54.7M) | (288K) | 1.1M | 1.0M | 956.7K | |
| Other Operating Expenses | 202.8M | 87.4M | 100.9M | 173.0M | 198.9M | 145.3M | |
| Operating Income | (178.8M) | (87.1M) | (100.8M) | (171.8M) | (154.6M) | (146.8M) | |
| Ebit | (44.0M) | (87.0M) | (99.2M) | (164.0M) | (147.6M) | (140.2M) | |
| Research Development | 153.6M | 55.0M | 52.8M | 58.9M | 67.7M | 97.4M | |
| Ebitda | (41.1M) | (86.7M) | (98.7M) | (163.5M) | (147.1M) | (139.8M) | |
| Cost Of Revenue | 1.9M | 55.0M | 427K | 85K | 76.5K | 72.7K | |
| Total Operating Expenses | 200.9M | 87.4M | 100.9M | 172.9M | 198.8M | 145.1M | |
| Net Income | (70.2M) | (88.3M) | (103.1M) | (177.1M) | (159.4M) | (151.4M) | |
| Income Tax Expense | 11.6M | 510K | 1.2M | 386.1K | 444.0K | 466.2K | |
| Selling General Administrative | 47.2K | 32.3M | 48.1M | 97.7M | 112.4M | 118.0M | |
| Income Before Tax | (58.6M) | (87.8M) | (101.9M) | (177.1M) | (159.4M) | (151.4M) | |
| Total Other Income Expense Net | (10.8M) | (668K) | (1.2M) | (5.4M) | (4.8M) | (5.1M) | |
| Net Income From Continuing Ops | (58.6M) | (87.8M) | (101.9M) | (157.9M) | (181.5M) | (190.6M) | |
| Non Operating Income Net Other | 3.4M | 3.8M | 134K | 1.6M | 1.8M | 1.9M | |
| Net Income Applicable To Common Shares | 130.1M | (58.6M) | (87.8M) | (101.9M) | (117.2M) | (123.1M) | |
| Interest Income | 2.8M | 134K | 1.6M | 6.2M | 5.6M | 5.9M | |
| Net Interest Income | (11.8M) | (668K) | (1.2M) | (2.6M) | (3.0M) | (3.1M) | |
| Reconciled Depreciation | 2.9M | 292K | 427K | 510K | 459K | 436.1K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.